DNER and cancer: Two seminal articles revealed the cancer-fighting and inflammation-reducing effects of BET inhibitors in 2010.1,20 The subsequent identification of an increasing number of BET inhibitors, which showed substantial preclinical anticancer efficacy in an extensive number of solid and hematological tumors, led to the initiation of clinical trials for a variety of cancer therapies.